### Note to Viewers and some Naysayers!!:After reading some...

### Note to Viewers and some Naysayers!!:

After reading some garbage by randoms, I wanted to share a quick note regarding my previous article post on Mesoblast (after CRL-2), drawing parallels with the journey of Momelotinib. Just like Momelotinib, which faced multiple setbacks including two Complete Response Letters (CRLs) before finally achieving FDA approval, Mesoblast has also navigated through similar challenges. These experiences underscore the rigorous and often lengthy process of drug development and approval.

Despite these hurdles, I remain confident in Mesoblast’s potential. The persistence and strategic efforts taken to address regulatory concerns will pave the way for its eventual success. It’s about time for Mesoblast to cross the finish line and emerge as a major, revenue-generating player in the biotech pharmaceutical sector. Our belief in its promise is stronger than ever!

I invite you to read and understand what it takes to be on this journey. In doing so, you might find a way to show respect for the founder and CEO, Dr. Silviu Itescu, and his dedicated team! Believed it then, now and in future!!

We must (& we will) win and get the remedy to the needy!!